Primaquine’s gametocytocidal efficacy in malaria asymptomatic carriers treated with dihydroartemisinin-piperaquine

Primaquine’s gametocytocidal efficacy in malaria asymptomatic carriers treated with dihydroartemisinin-piperaquine

Objectives

In this study, the investigators are interested to know if lower doses of Primaquine together with dihydroartemisinin-piperaquine can produce a similar effect of clearing both sexual and asexual parasites in asymptomatic carriers compared to the recommended dose of primaquine but with a decreased risk of haemolysis.

PI Institution(s)

Principal Investigator (PI)

Funding source(s)

Partner(s)

Abstract

The proposed study is a four-arm, open label, randomized, controlled trial. G6PD-normal asymptomatic P. falciparum infected individuals identified through population screening will be randomized to receive either a complete course of dihydroartemisinin-piperaquine (DHA-PPQ) alone (control arm) or a complete course of DHA-PPQ plus a single dose of PQ at 3 differing dose strengths (intervention arms), i.e. 0.75mg/kg, 0.4mg base/kg and 0.2mg base/kg.

The study is planned to enroll 1,200 individuals with an asymptomatic malaria infection during the rainy /transmission season (June - December) from villages around the MRC's field stations at Walikunda and Basse in The Gambia. Asymptomatic parasite carriers identified by qualitative (RDT) and quantitative (parasites counts >20/µl by slide microscopy) methods during population screening exercises. Further screening will be carried out to confirm eligibility, including tests for qualitative G6PD enzyme function (fluorescence spot test) and haemoglobin.

Clinical trial: Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers (PRINOGAM)

Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers

Key facts

  • Dates
    Jan 2013 to Dec 2015
    Funding information
    Research Grant MC_EX_MR/K007203/1
    Country
    • Gambia

MESA tags

  • Methodology
    Operational research, Product development & clinical research
    Theme(s)
    Asymptomatic reservoir, Drug-based strategies, Tools for elimination